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ABSTRACT
PLC-beta 1 (PLCβ1) inhibits in human K562 cells erythroid differentiation induced 
by mithramycin (MTH) by targeting miR-210 expression. Inhibition of miR-210 affects 
the erythroid differentiation pathway and it occurs to a greater extent in MTH-treated 
cells. Overexpression of PLCβ1 suppresses the differentiation of K562 elicited by 
MTH as demonstrated by the absence of γ-globin expression. Inhibition of PLCβ1 
expression is capable to promote the differentiation process leading to a recovery of 
γ-globin gene even in the absence of MTH. Our experimental evidences suggest that 
PLCβ1 signaling regulates erythropoiesis through miR-210. Indeed overexpression 
of PLCβ1 leads to a decrease of miR-210 expression after MTH treatment. Moreover 
miR-210 is up-regulated when PLCβ1 expression is down-regulated. When we silenced 
PKCα by RNAi technique, we found a decrease in miR-210 and γ-globin expression 
levels, which led to a severe slowdown of cell differentiation in K562 cells and these 
effects were the same encountered in cells overexpressing PLCβ1. Therefore we 
suggest a novel role for PLCβ1 in regulating miR-210 and our data hint at the fact that, 
in human K562 erythroleukemia cells, the modulation of PLCβ1 expression is able to 
exert an impairment of normal erythropoiesis as assessed by γ-globin expression.
INTRODUCTION
MicroRNAs (miRNAs) are small regulatory RNAs 
that regulate gene expression post-transcriptionally, 
including both inhibition of protein translation and 
mRNA degradation [1]. Indeed miRNAs are involved 
in the regulation of a variety of biological processes 
such as embryonic development, cell proliferation, and 
differentiation [2]. Altered expressions of miRNAs 
have been implicated in hematological malignancies 
[3]. In many cases, the identification of specific targets 
of miRNAs highlighted important cellular events and 
demonstrated that aberrant microRNA expression is a 
common feature of many diseases [4]. Several miRNAs 
were identified as deeply involved in the erythroid 
phenotype, including miR-15a, miR-16-1, miR-126, 
miR-144, miR-451 and miR-210 are believed to regulate 
several functions of erythroid cells such as maturation and 
proliferation of early erythroid cells, expression of fetal 
γ-globin genes and enucleation [5]. Recent studies have 
shown that dysregulation of miRNAs contributes to the 
initiation, progression, metastasis, and drug resistance of 
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cancer [6] and hematologic malignancy [7]. Previously, 
several miRNAs have been identified as being involved in 
hematopoiesis through their target genes. Moreover, miR-
223 enhances retinoic acid (RA)-induced granulocytic 
differentiation by targeting nuclear factor I/A (NFIA) 
[8] . In addition MiR-155 transduction greatly reduces 
both the myeloid and erythroid colony formation of 
normal human hematopoietic stem-progenitor cells [9], 
miR-221 and miR-222 inhibit normal erythropoiesis 
and erythroleukemia cell growth via kit protein down-
regulation [10] , miR-451 and GATA transcription 
factors were shown to comprise a regulatory circuit that 
modulates erythroid maturation [11-13], miR-210 is 
involved in increased expression of the γ-globin gene in 
differentiating erythroid cells [14]. K562, a myelogenous 
leukemia cell line arising from a highly undifferentiated 
progenitor of the erythrocytic and megakaryocytic 
lineages [15] with potential to megakaryocyte and 
erythroid differentiation, provides an excellent model 
system for investigating processes involved in cellular 
differentiation [16]. MiR-210 has been mechanistically 
linked to the control of a wide range of cellular responses 
known to influence normal cell developmental as well as 
a number of hypoxia-dependent disease states, including 
tissue ischemia, inflammation, and tumorogenesis [17]. 
Recently it has been described that miR-210 is a highly 
expressed miR in the erythroid precursor cells and is 
induced during MTH mediated erythroid differentiation 
of K562. MTH is a powerful inducer of erythroid 
differentiation and γ-globin gene expression in erythroid 
cells and namely of K562 erythroid differentiation, leading 
to accumulation of γ-globin mRNA and production of 
embryo-fetal haemoglobins [14,18]. The understanding 
of the regulatory mechanism of erythroid differentiation 
is of crucial importance in order to develop methods for 
the manipulation of hematopoietic stem cells suitable for 
the treatment of anemia. Our previous studies have shown 
that Phospholipase C β1 (PLCβ1) is a key molecule 
for nuclear inositide signaling, where it plays a role in 
cell cycle progression, proliferation and differentiation 
[19-23]. PLCβ1 is responsible for the hydrolysis of the 
phosphatidilinool-4,5-bisphophate (PIP2), generating 
the second messengers inositol-1,4,5-triphosphate 
and diacylglycerol. Nuclear PI metabolism changes 
during dimethyl sulfoxide (DMSO)-induced erythroid 
differentiation of FELC [24] and the nuclear localization 
of PLCβ1 is crucial for the differentiation of FELC in 
that PLCβ1 signaling targets the transcription factor 
p45/NF-E2, an enhancer binding protein for β-globin 
gene, whilst other transcription factors involved in 
erythroid differentiation, such as members of the GATA 
family, do not respond to nuclear PLCβ1 signaling [25]. 
Another nuclear PLC-β1 target identified by a proteomic 
approach is SRp20, a splicing factor that belongs to the 
serine/arginine-rich (SR) splicing factor family. PLC-β1 
and SRp20 physically interact in the nucleus and SRp20 
expression is down-regulated by the nuclear signaling 
evoked by PLC-β1 [26]. In addition, nuclear PLCβ1 up-
regulates the expression of CD24 in MEL cells. CD24 is 
an antigen involved in differentiation and hematopoiesis, 
it is considered a critical molecule for the metastasizing 
ability of solid tumors and it is overexpressed in a number 
of leukemias. Because of these assumptions we decided to 
investigate whether the PLCβ1 signaling pathway could 
be involved in MTH-induced erythroid differentiation 
of K562 cells and to examine whether PLCβ1 regulates 
miR-210 expression. Our results provide experimental 
support for the idea that PLCβ1 is involved in the control 
of erythroid differentiation by means of the regulation of 
miR-210 expression, likely through a PKCα-mediated-
pathway.
RESULTS
Characterization of PLCβ1 and γ-globin 
expression in erythroid cell culture
K562 cells can be induced to differentiate towards 
erythroid lineage by MHT. MHT is a highly glycosylated 
aureolic acid anticancer agent [27] a well-known inducer 
of K562 cells. In a previous study aimed at elucidating 
the functional role of PLCβ1 in the regulation of growth 
and differentiation of Friend erythroleukemia cells, 
we overexpressed PLCβ1 and we demonstrated that 
this overexpression was sufficient to block erythroid 
differentiation induced by DMSO and, therefore, to 
induce cell cycle progression. Thus, we analyzed whether 
PLCβ1 was present in K562 cell line. We performed 
western blot analysis using a specific antibody against 
PLCβ1. As we show in fig.1 our antibody recognize 
this PLC in whole cell extract. Then we analyze the 
presence of PLCβ1 during erythroid differentiation and 
we observed that PLCβ1 content was decreased in MTH-
treated K562 cells as expected. β-tubulin was used as 
loading control. To validate at the transcriptional level 
the data obtained by western blot analysis, cells from 
the same samples were used for mRNA extraction and 
cDNA synthesis for real-time PCR. PLCβ1 mRNA level 
decreased after induction of differentiation in respect to 
protein expression data. Moreover, the effect of MTH 
on the mRNA levels of γ-globin in K562 cultures was 
determined by quantitative RT-PCR. The cells were 
induced to erythroid differentiation by 30 nM MTH. 
Five days after 30nM MTH treatment K562 cells showed 
signs of erythroid differentiation. By this time γ-globin is 
expressed at a very high level showing that the majority of 
the cells are committed to the differentiation program. In 
fact, by comparison, MTH stimulated γ-globin expression 
increased by about five fold, compared to the same day 
control throughout the time period of the experiment. 
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This suggested that MTH was able to induce K562 cells 
towards erythroid differentiation along with the elevated 
expression of γ-globin. In agreement with the known 
behavior of nuclear inositide signaling [28] five days of 
erythroid differentiation largely decreases the expression 
of PLCβ1 as shown in fig. 1. Taken together, the present 
data demonstrates that MTH suppressed expression of 
PLCβ1 during K562 differentiation program, suggesting 
an important role for this protein in the regulation of 
erythropoiesis.
Effect of PLCβ1 silencing and overexpression on 
MTH induced K562 differentiation
To determine the functional role triggered by 
PLCβ1 during the erythroid differentiation, we performed 
expression experiments in wild type K562 cells, in cells 
in which PLCβ1 was overexpressed and in cells in which 
the PLCβ1 expression was knocked-down. The analysis 
of the PLCβ1 phenotype in the stable transfectants we 
obtained is shown in fig. 2A. The western blot analysis 
of these clones shows that we have obtained effectively 
stable clones of K562. mRNA was extracted, retro 
transcribed, and quantified by real-time PCR. Analysis of 
the PLCβ1 mRNA levels showed that both silencing and 
overexpressing actually occurred, in agreement with the 
variation of protein level shown in Fig. 2A. An analysis of 
the effect of differentiation program induced by MTH on 
PLCβ1 phenotype in the stable transfectants we obtained 
is shown in Fig. 2B. Cells transfected with the empty 
vector (mock) behave exactly as the original untransfected 
K562 cells do, in that PLCβ1, is down-regulated upon 
treatment with MTH. The same panel shows that when 
overexpressed, PLCβ1, is no longer down-regulated 
indicating that the overexpression of PLCβ1 determines 
a resistance to MTH treatment. Moreover the PLCβ1 
KD shows an almost complete loss of expression both 
in the absence and in the presence of MTH, as expected. 
Hemoglobinization induction of K562 cells was efficient 
after MTH treatment. Erythroid differentiation was 
monitored using analysis of γ-globin transcripts by qRT-
PCR. As shown in Fig. 2C, differentiation of wild-type 
K562 is characterized by activation of γ-globin gene 
expression. Moreover, transcription levels of γ-globin were 
elevated during MTH induced erythroid differentiation, 
but we observed a decrease of hemoglobinization in the 
samples in which PLCβ1 was overexpressed even in the 
presence of MTH. Further, cellular knockdown of PLCβ1 
results in an increase of γ-globin expression of untreated 
cells but the highest level of hemoglobinization is observed 
after MTH treatment. Nevertheless, these findings provide 
a clear evidence of the critical involvement of the PLCβ1 
in the differentiation process of MTH induced K562 cells.
Expression of miR-210 in MTH-treated K562
Recent data identify a novel miR-210, whose 
expression is enhanced in association with erythroid 
differentiation and induction to fetal hemoglobin (HbF) 
production. The aim of this study was to investigate the 
PLCβ1 effect on miRNA-210 expression after MTH 
treatment. We employed both growing and differentiating 
cells harvested 5 days after MTH stimulation. Fig. 3A 
shows the expression of the analyzed miR-210 when RNA 
from K562 cells treated for 5 days with MTH is compared 
to that isolated from control untreated cells. Expression 
of the miRNA-210 in MTH-treated cells was determined 
by qRT-PCR. As it is clearly appreciable, during erythroid 
induction of K562 cells miR-210 expression increases. 
Then we analyzed the effects of overexpression and the 
effect of loss of function of this enzyme in K562 cells 
after 5 days of MTH administration. In proliferating K562 
cells, cells transfected with PLCβ1 show no significant 
difference in the level of miR-210 compared to vector 
transfected cells. On the other hand, K562 cells silenced 
for the expression of the PLCβ1 show an increase of 
miR-210 levels as compared to control cells. The level of 
endogenous miR-210 in K562 control cells cultured for 
five days with MTH was increased as we expected. As it is 
clearly appreciable, during erythroid induction of PLCβ1 
Fig 1: PLCβ1 expression decreases during erythroid 
MTH induction of human K562 cells. Cells were grown 
in complete RPMI 10% FBS for two days and, then, divided in 
two aliquots: one was seeded in complete RPMI 10% FBS and 
the other one in complete RPMI 10% FBS supplemented with 
mithramaycin (MTH) to a final concentration of 30 nM. K562 
cells were harvested after 5 days of growth in proliferating (wild 
type) or differentiation medium (5 days M). Cells were then 
lysed to extract RNA and proteins. Western blotting analyses 
were carried out with specific antibodies against PLCβ1 and 
β-tubulin. The extracted RNA was retro-transcribed and real-
time PCR was performed to evaluate the quantitative expression 
of PLCβ1 and γ-globin. As shown, PLCβ1 highly decreases after 
5 days of differentiation both in Western Blotting and in real-time 
PCR. γ-globin expression was used to check the differentiation 
of K562 cells. 
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overexpressing K562 cells we assist to a dramatic decrease 
of miR-210 expression. Moreover, PLCβ1 silencing 
resulted in an increase in miR-210 expression after 5 
days of MTH administration, even if only slightly, as 
compared with wild type differentiating cells. To examine 
the effect of modulated levels of PLCβ1 on erythroid 
differentiation of K562 cells, we evaluated, in the same 
samples, the expression of γ-globin. Western blot analysis 
(Fig. 3b) showed that amplified levels of PLCβ1 act to 
negatively regulate γ-globin protein levels after MTH 
treatment. On the contrary, the knockdown of PLCβ1 was 
able to increase the expression of γ-globin in K562 cells 
as compared with control cells even in the absence of the 
differentiating agent MTH. To investigate the contribution 
of miRNA-210 to erythroid cell differentiation under 
MTH treatment, loss of function study was performed 
using the anti-miR-210. The result showed that 
transfection of K562 cells with 10nM anti-miR-210 
Fig 2: Effect of PLCβ1 modulation on the MTH erythroid differentiation of K562 cells. A) Clones were analyzed by 
Western Blotting and Real-Time PCR to check the efficiency of PLCβ1 gene silencing (PLCβ1 KD) and the efficiency of PLCβ1 protein 
overexpression (PLCβ1 OV) respect to the controls (control). As shown PLCβ1 is respectively overexpressed and silenced in PLCβ1 OV 
and PLCβ1 KD if compared to control cells. B) Clones were grown in complete RPMI 10% FBS for two days and seeded in complete 
RPMI 10% FBS or in complete RPMI 10% FBS supplemented with mithramaycin to a final concentration of 30 nM. Cycling cells (wild 
type) and differentiating cells were harvested after 5 days of growth respectively in proliferating or differentiating condition (5 days M). 
Cells were then lysed to extract RNA and proteins. Proteins lysates were loaded at the same volume and protein concentration on an 8% 
SDS-PAGE gel. Western blotting analyses were carried out with specific antibodies against PLCβ1 and β-tubulin. The extracted RNA was 
retro-transcribed and real-time PCR was performed to evaluate the quantitative expression of PLCβ1. C) Clones were treated as in b) and 
γ-globin quantitative expression was evaluated by real-time PCR analysis. All results are representative of two different experiments using 
three separate clones of each sample.
Oncotarget4226www.impactjournals.com/oncotarget
caused a significant reduction of miR-210 levels (Fig. 4). 
Determination of γ-globin expression in the presence of 
anti-miR-210 showed a partial but significant reduction of 
γ-globin mRNA levels under the MTH treatment at 72 h. 
Transfection with scramble (scr) caused no effect. Taken 
together, these results thus suggest that PLCβ1 signaling 
is involved in the erythroid differentiation process as 
assessed by γ-globin induced by MTH through miR-210 
regulation and that this process is likely dependent on the 
amount of PLCβ1 expression level.
PLCβ1 regulates miR-210 through PKCα 
In order to further investigate the pathway 
through which PLCβ1 could modulate miR-210 and 
cell differentiation in K562 cells, we investigated the 
possible role of PKCs, known to be direct targets of 
PLC signaling. Overexpression of PLCβ1 led to a strong 
decrease in PKCα levels if compared with the controls 
(Fig. 5a); meanwhile, PKCβII and PKCζ levels were not 
affected at all (data not shown and ref. 39). These data 
showed a possible connection between PLCβ1, PKCα and 
miR-210 modulation in K562 cell differentiation. Then, 
we transiently transfected K562 cells to silence PKCα 
through RNAi technique. Cells were transfected with 
specific siRNA for PKCα and scrambled one as control. 
Twenty-four hours after the transfection, we induced K562 
differentiation with MTH for 5 days and the expression 
of both miR-210 and γ-globin have been analyzed. 
Interestingly, as reported in Fig. 5b, cells characterized 
by silenced PKCα showed a significant decrease of miR-
Fig 3: Effect of PLCβ1 expression on miRNA-210 after MTH treatment. a) The figure shows the fold expression of the analyzed 
miR-210 in K562 control cells and in cells in which the expression of PLCβ1 is modulated. K562 cells were induced to differentiate with 
30nM of MTH for 5 days. Real-Time PCR analysis of the expression of mir-210 was performed using let-7c expression as housekeeping 
control. b) Stably transfected K562 cells were differentiated and the level of differentiation was analyzed by γ-globin expression in the 
presence and in the absence of MTH. All results are representative of two different experiments using three separate clones of each sample.
Fig 4: Loss of function study of miR-210. Inhibition of miR-210 activity by using anti-miR-210 treatment in K562 cells showed a 
significant depletion of miRNA-210 level as well as globin expression. K562 cells were induced to differentiate with 30nM of MTH for 5 
days. The mean and standard deviation values were from 3 independent experiments.
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210 and γ-globin expression if compared with the one 
transfected with scrambled siRNA. Moreover to examine 
the effect of decreased levels of PKCα on erythroid 
differentiation, we evaluated, in the same samples, the 
expression of miR-210. As can be seen in Fig. 5c, miR-210 
levels increased in differentiated cells, but PKCα knock-
down cells did not show increase of miR-210 levels. These 
data confirmed that PLCβ1 can regulate miR-210 levels 
through PKCα signaling pathway.
DISCUSSION
In this study, we used human erythroleukemia K562 
cells as an in vitro model of erythropoiesis because they 
have been proven to be a powerful tool for investigating 
erythroid cell development. To address the functional 
relevance of PLCβ1 in erythropoiesis, we have modulated 
PLCβ1 expression into MTH treated K562 cells and 
studied its effect on erythroid differentiation and miR-210 
profile. The DNA binding drug MTH is a potent inducer 
of γ-globin mRNA accumulation and fetal hemoglobin 
production in erythroid cells from healthy human subjects 
and β-thalassemia patients [18]. MiR-210 is an important 
microRNA target that has been demonstrated to be 
associated with MTH-mediated induction of erythroid 
differentiation of leukemic K562 cells and HbF production 
in erythroid precursor cells from β-thalassemia patients 
[14]. In fact, Bianchi et al. demonstrated that MTH 
is a powerful inducer of erythroid differentiation and 
γ-globin gene expression in human erythroid cells. Our 
results suggest that PLCβ1 signaling is involved in the 
differentiation process induced by MTH by regulating 
both γ-globin and miR-210 expression. Indeed PLCβ1 
overexpression inhibits erythroid differentiation of the 
erythroid lineage K562 cell line. Therefore, cellular 
knockdown of PLCβ1 causes a significant up-regulation 
of γ-globin expression. This indicates that the level 
of expression of PLCβ1 is able to affect the erythroid 
potential of these cells. In the current study we identified 
miR-210 as a target of PLCβ1. In fact we observed that 
PLCβ1 overexpression led to a loss of induction of miR-
210 expression after MTH treatment. Moreover, K562 
cells silencing for the expression of the PLCβ1 induces 
an increase of miR-210 levels. Enhanced PLCβ1 level 
and reduced miR-210 level accompanies erythroid 
differentiation. This suggest that the role of PLCβ1 during 
erythropoiesis is linked to that of miR-210 even though 
our results do not fully explain the mechanism of action of 
PLCβ1 within the cells but the results obtained are indeed 
compatible with previously results that demonstrated 
a role for PLCβ1 in erythropoiesis [24,25] .We also 
showed that inhibition of miR-210 caused the significant 
reduction of globin gene expression in K562 erythroid cell 
line. Interestingly, we found that PKCα levels decreased 
in cells where PLCβ1 was overexpressed. All in all, the 
data presented in this study suggest that an enhanced 
PLCβ1 signaling could lead, through generation of second 
messengers, to a sustained activation of PKCα and then to 
its degradation. At any rate, the mechanism that links these 
two proteins will be further investigated in the future. 
When we silenced PKCα by RNAi technique, we found 
a decrease in miR-210 and γ-globin expression levels, 
which led to a severe slowdown of cell differentiation in 
K562 cells and these effects were the same encountered in 
cells overexpressing PLCβ1. Hematopoiesis is a multistep 
process leading to the production of mature blood cells, 
Fig 5: PKCα levels decrease in K562 cells overexpressing PLCβ1. a) Cell lysates were loaded at the same volume and protein 
concentration on a SDS-PAGE 10% gel, and western blotting analyses were performed with specific antibodies for PKCα. As shown, PKCα 
was characterized by a down modulation of its expression in cells overexpressing PLCβ1 in the presence and also in the absence of MTH; 
b) PKCα knockdown: K562 cells were transiently transfected with a specific siRNA to knockdown PKCα (PKCα) or with a scrambled 
(scr) one as negative control. Western blotting analyses were performed with specific antibodies for PKCα, γ-globin and β-tubulin. c) The 
figure shows the fold expression of the analyzed miR-210 in K562 control cells and in cells in which the expression of PKCα is knocked-
down in presence and absence of MTH. Real-Time PCR analysis of the expression of mir-210 was performed using let-7c expression as 
housekeeping control. Results were the mean from three separate experiments ± SD.
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and is controlled by many factors, including miRNAs. 
MiR-210 is a member of a new class of regulatory 
miRNAs that play an important role in erythroid 
maturation [29]. MiR-210 is induced in time-dependent 
and dose dependent manner during MTH-mediated 
erythroid induction of K562 cells. Moreover, miR-210 
is induced following MTH-treatment also in erythroid 
precursor cells from human donors [14]. MiR-210 has 
been recently associated with hypoxia [30-33]. MiR-210 
was also found up-regulated in most solid tumors and its 
expression correlates with an adverse clinical outcome and 
with metastatic potential [34,35]. In keeping with these 
data, miR-210 has been proposed as a novel tumor hypoxia 
marker [36]. Recently it has been demonstrated that 
Pancreatic Stellate cells induce the expression of miR-210 
in pancreatic cancer cells [37]. In this cellular model MiR-
210 up-regulation is inhibited by inhibitors of ERK and 
PI3K/Akt pathways . It was already known that PLCβ1 
is down-regulated when Friend erythroleukemia cells 
treated with DMSO differentiate and synthesize β-globin 
[38]. Another study on the effects of the overexpression 
of PLCβ1 showed a specific and positive connection 
between cyclin D3 and PLCβ1 in K562 cells, which led 
to a prolonged S phase of the cell cycle and a delay in 
cell proliferation in that PLCβ1 targets cyclin D3, likely 
through a PKCα-mediated-pathway and, as a downstream 
effect of its activity, K562 cells undergo an accumulation 
in the S phase of the cell cycle [39]. PLCβ1 interacts with 
a number of proteins involved in cellular processes, and 
in different experimental models [20,40] . Very recently 
Scarlata et al. have shown that PLCβ1 can affect the 
siRNA activity of genes for two metabolic enzymes, 
GAPDH and LDH, through its interaction with TRAX 
( translin-associated factor X) [41] which is a strong 
binding factor of PLCβ1 [42,43]. To find out new PLCβ1 
molecular targets, different from proteins, such as miRNA 
could give rise to new and unexpected findings that are 
important for understanding the role of this pathway 
in physiology and pathology as well as in the mode of 
action of DNA binding drugs such as MTH which is a 
potent inducer of γ-globin mRNA accumulation and HbF 
production in erythroid cells from healthy human subjects 
and β-thalassemia patients [18]. On the whole our data 
hint at a new pathway leading to erythroid differentiation 
that links PLCβ1 signaling with the expression of miR-210 
and eventually of γ-globin.
MATERIALS AND METHODS
Culture conditions
Human leukemia K562 cells were cultured in 
humified atmosphere of 5% CO2/air in RPMI 1640 
medium (Sigma, St Louis, MO, USA), 10% fetal bovine 
serum (Sigma Chemical St Louis, MO). To induce 
erythroid differentiation the cells (106/mL) were treated 
with 30nM mithramycin (Sigma Chemical St Louis, MO) 
for 3 or 5 days.
Transfections and isolation of clones. Cells 
were transfected with full-length DNA vectors for 
human PLCβ1a and cloned into pcDNA/2.1 plasmids. 
Overexpression of PLCβ1 was performed using 
Lipofectamine 2000 from Invitrogen. Cells were seeded 
at a cell density of 5*105/ml in 25ml flasks in which 
was added the mix of Lipofectamine 2000 and the right 
vectors, following manufacturer’s instructions. Cells 
were collected to be analyzed 24h after the transfections. 
To obtain stable clones, cells were selected by limiting 
dilution in complete RPMI 1640 10% FBS containing 
Geneticin (G418 from Sigma Aldrich) at a concentration 
of 1000μg/ml 24h after the transfection, then expanded 
and kept always in selection with G418. The expression 
of PLCβ1 was silenced using RNAi techniques with the 
electroporation assay kit by Thema Ricerca. Cells, plated 
at a cell density of 5*105/ml before the transfection, were 
resuspended in 100μl of Mirrus Solution (pre-warmed at 
37°C); specific siRNAs were added at the suspension and 
the mix moved in proper cuvettes. Using program T-16, 
cells were electroporated in Nucleofector I (Amaxa). 
Afterwards, cells were plated in 25ml flasks with 5ml of 
complete RPMI 1640 10% FBS. The following siRNA was 
used at a concentration of 50nM: for PLCβ1 (Ambion) 
and as negative control (scrambled), S00J1C8 (Ambion). 
PKCα Knock-down: the expression of PKCα was silenced 
using RNAi techniques with the electroporation assay kit 
by Thema Ricerca. Cells, plated at a cell density of 5 × 
105/ml before the transfection, were resuspended in 100 μl 
of Mirrus solution (prewarmed at 37°C); specific siRNAs 
were added at the suspension and the mix moved in proper 
cuvettes. Using program T-16, cells were electroporated in 
Nucleofector I (Amaxa). Afterwards, cells were plated in 
25 ml flasks with 5 ml of complete RPMI 1640 10% FBS. 
The following RNAis were used at a concentration of 50 
nM: for PKCα, PRKCA s11092 (Ambion) and as negative 
control (scrambled), S00J1C8 (Ambion).
RNA isolation and MicroRNA analysis
Total RNA was isolated by miRVana miRNA 
isolation Kit (Ambion by life technology) according to 
the manufacture instructions. The Nanodrop2000 UV-Vis 
Spectrophotometers was used to determine the integrity 
and measure the concentration of total RNA samples 
(Thermo Scientific Inc). For microRNA quantization 
reverse transcriptase reactions were performed using 
TaqMan MicroRNA Revese Transcription Kit (Applied 
Biosystems for hsa-miR-210 and the 7700 Sequence 
Detection System version 1.7 (Applied Biosystems, Foster 
City, CA, USA). Relative expression was calculated using 
the comparative cycle threshold method and as reference 
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genes the endogenous control human 18S kit human 18S 
rRNA and hsa-let-7c microRNA. Anti-miR-210 inhibitor 
transfection: anti-miR™ miRNA inhibitor (Applied 
Biosystems, Foster City, CA), single-stranded RNA-
based inhibitor was used for inhibition of miRNA activity. 
MiR-210 inhibitor (anti-miR-210) or negative control 
molecules (scrambled oligonucleotide) were transfected 
into K562 cells or day 7 erythroid precursor cells using 
Lipofectamine 2000 (Invitrogen Carlsbad, CA) at a final 
concentration of 10 nM.
Western Blotting
Approximately 2.5 × 106 cells were harvested at 
indicated time points, washed twice in PBS, resuspended 
in RIPA lysis buffer (50 mM Tris-HCl at pH 7.4, 150 mM 
NaCl, 0.1% SDS, 1% NP-40, 0.25% sodium deoxycholate, 
protease inhibitors coktail (Roche)), and incubated for 10 
min on ice. After centrifugation at 14,000 rpm for 5 min at 
4°C to remove cellular debris, the remaining supernatant 
was transferred to a new tube, supplemented with sample 
buffer, and incubated for 10 min at 60°C. Proteins were 
separated by SDS gel electrophoresis using the NuPAGE 
Bis-Tris gel system (Invitrogen) and MOPS running 
buffer under reducing conditions. Subsequently, proteins 
were transferred onto a nitrocellulose membrane using the 
NuPAGE transfer buffer (Invitrogen). Membranes were 
blocked with 5% milk-PBST for at least 1 h and probed 
with PLCβ1 rabbit polyclonal antibody (R-233; sc-9050, 
Santa Cruz Biotechnology) at a 1:500 dilution, or β-tubulin 
mouse monoclonal from Sigma-Aldrich at a 1:10000 
dilution in PBST for 1 h at room temperature or overnight 
at 4°C. PKCα was from Cell Signaling Technology). 
Membranes were washed four times with PBST, incubated 
with sheep anti-mouse or anti-rabbit peroxidase-coupled 
secondary antibodies (NA931 and NA934, GE Healthcare) 
at a 1:2000 dilution in 2.5% milk-PBST for 1 h at room 
temperature, washed three times with PBST, and incubated 
for 2 min with Western Lightning Plus-ECL substrate 
(Perkin Elmer). Proteins were visualized by exposure to 
scientific imaging film (Kodak).
Quantitative RT–PCR
Isolation of RNA was performed using the 
miRNeasy minikit (Qiagen). RNA was quantified by 
a NanoDrop spectrophotometer (Thermo Scientific). 
Reverse transcription was carried out using the iScript 
cDNA synthesis kit (Bio-Rad). Real-time PCR was 
performed using the ABI 7900 Machine Real-Time PCR 
system and SYBR Green PCR Master Mix (Applied 
Biosystems). To determine PLCβ1 and γ-globin 
expression, the samples used for the reporter gene assay 
were harvested, and total cellular RNA was extracted 
using the RNeasy mini kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s instructions. After the 
measurement of the RNA concentration, cDNA was 
synthesized starting from 2 μg of total RNA using 200 
U of M-MLV retrotranscriptase (Promega, Madison, WI, 
USA), 0.5 μg of oligo-dT primers, 25 U ribonuclease 
inhibitor, and 10 mM of each dNTP. The reactions were 
incubated for 1 h at 42°C. The expression of PLCβ1 
and γ-globin genes was determined by using a TaqMan-
based real-time PCR method (Applied Biosystems, 
Foster City, CA, USA). Their expression levels were 
analyzed and quantified by means of TaqMan-specific 
probes Hs01008373 for PLCβ1 (Applied Biosystems) ; 
Hs00361131_g1 for γ-globin. GAPDH was used as the 
reference housekeeping gene (Mm99999915_g1; Applied 
Biosystems). All real-time PCR reactions were performed 
in a MicroAmp Optical 96-well reaction plate (Applied 
Biosystems) in a total reaction volume of 25 μl, using 
12.5 μl of TaqMan PCR universal master mix (Applied 
Biosystems), 1.25 μl of the desired gene expression assay 
mix containing the primers and probes, and 1 μl of cDNA. 
Each reaction was repeated in triplicate. Reactions were 
carried out using the ABI Prism 7300 sequence detection 
system (Applied Biosystems) with the following thermal 
conditions: 50°C for 2 min and 95°C for 10 min, followed 
by 40 cycles of 95°C for 15 s, and 60°C for 1 min. The 
ΔΔCt method was used to quantitate amounts of each gene 
relative to the GAPDH amount in each reaction, according 
to the manufacturer’s protocol (Applied Biosystems). The 
results of different sets of experiments were statistically 
analyzed by GraphPad Prism 3.02 software (GraphPad, 
San Diego, CA, USA). 
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